Natriuretic Peptides: Role in Current Cardiology

Cover Page

Cite item


Natriuretic peptides were discovered in 50–70s of the XX century. BNP was more diagnostically and prognostically significant, as it is secreted directly into the ventricles of the heart. The studies demonstrated a high predictive value of increasing the level of BNP in acute decompensation of heart failure and in patients with chronic heart failure in a study of Val-HeFT. It was demonstrated that monitoring the level of NT-proBNP can be used for the selection of optimal therapy, affect the course and outcome of the disease, and reduce the cost of treatment. The next step in learning BNP was to undertake attempts of their use in the therapy of heart failure. Long-term therapy BNP (drug nesiritide) improved left ventricular remodelling in patients with stable heart failure. Currently the definition of the levels of BNP and NT-proBNP is used for the diagnosis and management of patients with heart failure.

About the authors

G. A. Burnasheva

Sechenov First Moscow State Medical University, Moscow, Russian Federation

Author for correspondence.

доктор медицинских наук, профессор кафедры факультетской терапии № 1 лечебного факультета Первого МГМУ им. И.М. Сеченова Адрес: 119991, Москва, ул. Трубецкая, д. 8, с. 2, тел.: +7 (499) 248-53-30

Russian Federation

D. A. Napalkov

Sechenov First Moscow State Medical University, Moscow, Russian Federation


студентка 6-го курса лечебного факультета Первого МГМУ им. И.М. Сеченова Адрес: 119991, Москва, ул. Трубецкая, д. 8, с. 2, тел.: +7 (499) 248-53-30

Russian Federation


  1. Kirsh B. Electronmicroscopy of the atrium of the Guinea pig heart. Exp. Med. Surg. 1956; 14: 99–112.
  2. Marie J.P., Guillemont H., Hatt P.Y. Le degre de granulation des cardiocytes auriculaires. Etude planimetriques au cours de differents apports d’eau et de sodium chez le rat. Pathol. Biol. (Paris). 1976;24: 549–554.
  3. Henry J.P., Pearce J.W. The possible role of cardiac atrial stretch receptors in the induction of changes in urine flow. J. Physiol. 1956; 131: 572–585.
  4. De Bold A.J., Borenstein H.B., Veress A.T., Sonnenberg H. Rapid and important natriuretic response to intravenous injection of atrial myocardial extracts in rats. Life Sci. 1981; 28: 89–94.
  5. Dahlen J.R. B-Type Natriuretic Peptide: Biochemistry and Measurement. In: Cardiac Markers. Ch. 23. A.Wu. Totowa (ed.). New Jersey. 2003. P. 369–377.
  6. Levin E.R., Gardner D.G., Samson W.K. Natriuretic Peptides. N. Engl. J. Med. 1998; 339: 321–328.
  7. Weber M., Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart. 2006; 92: 843–849.
  8. Chauhan S.D., Nilsson H., Ahluwalia A., Hobbs A.J. Release of C-type natriuretic peptide accounts for the biological activity of endothelium derived hyperpolarizing factor. Proc. Natl. Acad. Sci USA. 2003; 100 (3): 1426–1431.
  9. Stingo A.J., Clavell A.L., Heublein D.M., Wei C.M., Pittelkow M.R., Burnett J.C. (Jr.). Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma. Am. J. Physiol. 1992; 263 (4 Pt. 2): 1318–1321.
  10. Chen H.H., Burnett J.C. (Jr.). C-type natriuretic peptide: the endothelial component of the natriuretic peptide system. J. Cardiovasc. Pharmacol. 1998; 32 (Suppl. 3): 22–28.
  11. Kalra P.R., Anker S.D., Struthers A.D., Coats A.J. The role of C-type natriuretic peptide in cardiovascular medicine. Eur. Heart J. 2001; 22 (12): 997–1007.
  12. Wiley K.E., Davenport A.P. Physiological antagonism of endothelin-1 in human conductance and resistance coronary artery. Brit. J. Pharmacol. 2001; 133 (4): 568–774.
  13. Drewett J.G., Fendly B.M., Garbers D.L., Lowe D.G. Natriuretic peptide receptor B (guanylyl cyclase B) mediates C-type natriuretic peptide relaxation of precontracted rat aorta. J. Biol. Chem. 1995; 270 (9): 4668–4674.
  14. Clerico A., Recchia F.A., Passino C. Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am. J. Physiol. 2006; 290: 17–29.
  15. De Lemos J.A., McGuire D.K., Drazner M.H. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003; 362(9380): 316–322.
  16. Burnett J., Kao P., Hu D., Heser, D. W., Heublein, D., Granger, J.P. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science. 1986; 231: 1145–1147.
  17. Lerman A., Gibbons R., Rodeheffer R. Circulatory N terminal ANP as a marker for symptomless LV dysfunction. Lancet. 1993;341: 1105–1109.
  18. Motwani J., McAlpine H., Kennedy N., Struthers A. Plasma brain natriuretic peptide as an indicator for angiotensin converting enzyme inhibition after myocardial infarction. Lancet. 1993; 341:1109–1113.
  19. Hall C. The value of natriuretic peptides for the management of heart failure: current state of play. Eur. J. Heart Fail. 2001; 3:395–397.
  20. Galyavich A.C., Meryasev S.N., Galyavich P.A. Assessment of the severity and prognosis of chronic heart failure with N-terminal brain natriuretic peptide. Kazanskii meditsinskii zhurnal = Kazan medical journal. 2009;3:319–323.
  21. Osipova O.A. Evaluation of neurohormonal systems in patients with chronic heart failure due to post-infarction cardiosclerosis. Chelovek i ego zdorov'e = Man and his health. 2010;1:44–48.
  22. Cowie M., Struthers A., Wood D., Coates A.J.S., Thompson S.G., Poole-Wilson P.A. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997; 350: 1349–1353.
  23. Tsutamoto T., Wada A., Maeda K., Fukai D. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure. Circulation. 1997; 96: 509–516.
  24. Clerico A., Emdin M. Diagnostic Accuracy and Prognostic Relevance of the Measurement of Cardiac Natriuretic Peptides: A Review. Clin. Chem. 2004; 50: 33–50.
  25. Cheng V., Kazanegra R., Garcia A., Krishnaswamy P., Gardetto N., Clopton P., Maisel A. A rapid bedside test for В-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. JACC. 2001; 37: 386–391.
  26. Dao Q., Krishnaswamy P., Kazanegra R., Harrison A., Amirnovin R., Lenert L., Clopton P., Alberto J., Hlavin P. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent care setting. JACC. 2001; 37: 379–385.
  27. Anand I., Fisher L., Chiang Y.T. , Latini R, Masson S., Maggioni A.P., Glazer R.D., Tognoni G., Cohn J.N. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the valsartan heart failure trial (Val–Heft). Circulation. 2003; 107: 1276–1281.
  28. Galvani M., Ferrini D., Ottani F. Natriuretic peptides for risk stratification of patients with acute coronary syndromes. Eur. J. Heart Failure. 2004; 6: 327–334.
  29. Murdoch D.R., McDonagh T.A., Byrne J., Blue L., Farmer R., Morton J.J., Dargie H.J. Titration of vasodilator therapy in chronic heart failure to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored vs. empirical therapy. Am. Heart J. 1999; 138:1126–1132.
  30. Troughton R.W., Frampton C.M., Yandle T.G. et al.Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126-1130.
  31. Richards A.M., Doughty R., Nicholls M.G. , MacMahon S., Sharpe N., Murphy J., Espiner E.A., Frampton C., Yandle T.G. for the Australia — New Zealand Heart Failure Group. Plasma N terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. J. Am. Coll. Cardiol. 2001; 37:1781–1787.
  32. Mills R.M., Le Jemtel T.H., Horton D.P., Liang C., Lang R, Silver M.A., Lui C., Chatterjee K. Sustained hemodynamic effects of an infusion of nesiritide (human β–type natriuretic peptide) in heart failure. J. Am. Coll. Cardiol. 1999; 34: 155– 162.
  33. Colucci W.S., Elkayam U., Horton D.P., Elkayam U., Horton D.P., Abraham W.T., Bourge R.C., Johnson A.D., Wagoner L.E., Givertz M.M., Liang C.S., Neibaur M., Haught W.H., LeJemtel T.H. for the Nesiritide Study Group. Intravenous Nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N. Engl. J. Med. 2000; 343, 4: 246–253.
  34. James B.Y. VMAC Committees. Intravenous Nesiritide vs Nitroglicerin for treatment of decompensated congestive heart failure. JAMA. 2002; 287: 1531–1540.
  35. O’Connor C.M., Starling R.C., Hernandez A.F., Armstrong P.W., Dickstein K., Hasselblad V., Heizer G.M., Komajda M., Massie B.M. Effect of nesiritide in patients with acute decompensated heart failure. N. Engl. J. Med. 2011; 365: 32–43.
  36. Chen H.H., Glockner J.F., Schirger J.A., Cataliotti A., Redfield M.M., Burnett J.C. (Jr.). Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide. J. Am. Coll. Cardiol. 2012; 60: 2305–2312.
  37. McMurray J.J., Adamopoulos S., Anker S.D., Auricchio A., Böhm M., Dickstein K., Falk V., Filippatos G., Fonseca C., Gomez-Sanchez M.A., Jaarsma T., Køber L., Lip G.Y., Maggioni A.P., Parkhomenko A., Pieske B.M., Popescu B.A., Rønnevik P.K., Rutten F.H., Schwitter J., Seferovic P., Stepinska J., Trindade P.T., Voors A.A., Zannad F., Zeiher A. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 2012; 14 (8):803–869.

Comments on this article

Copyright (c) 2015 "Paediatrician" Publishers LLC

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies